Partnering with Industry: Best Practices Module (Page 13)
Transcript of Interview with Andy Dahlem, PhD
I see lots of opportunities for academia and industry to collaborate in new and even bigger ways. Part of it is driven by our pharmaceutical industries business model. Frankly, it costs too much and takes too long to discover new medicines today, and we’re looking for alternatives that can help us in the journey to discover and develop new medicines and get them to patients quicker. Academic institutions are under pressure today for things like funding. The basic business model for academia is probably under unprecedented challenge with flat or declining state funding, flat, maybe declining against inflation, federal funding, and rising tuition and fee charges for students are becoming not sustainable. Flat philanthropy in the tough markets we have today. All of that’s pushing academia and industry closer together to try and find ways to overlap and create synergies that could bring new inventions to patients in need. The external environment right now creates a unique opportunity at this unique moment where industry needs some solutions, particularly in drug discovery and development space, where brilliant minds in academia could collaborate with us in helping to facilitate our business processes, and there’s a motivation on the side of academia for better and deeper collaborations driven by some need to also solve funding challenges.
This interview is from the UIDP module, Partnering with Industry: Best Practices. Download the entire module here:
Download the first module in this series, Compliance, here: